Feb 28, 2024 / 09:30PM GMT
Operator
Welcome to the Iovance Biotherapeutics conference call to discuss the full-year 2023 results and recent corporate updates. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions). Please note that this conference is being recorded.
I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications, Iovance. Sara, you may begin.
Sara Pellegrino - Iovance Biotherapeutics Inc - Senior Vice President, Investor Relations and Corporate Communications
Thank you, operator. Good afternoon and thank you for joining our conference call and webcast to discuss full-year 2023 results and recent corporate updates. Dr. Fred Vogt, our Interim President and Chief Executive Officer, will provide a brief introduction. Jim Ziegler, EVP Commercial, will highlight our initial insights for the US commercial launch of Amtagvi following the recent Food and Drug Administration or FDA approval in advanced melanoma. Igor Bilinsky, Chief Operating Officer, will highlight commercial manufacturing and
Q4 2023 Iovance Biotherapeutics Inc Earnings Call Transcript
Feb 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers